Af­ter mixed pipeline up­dates, Re­genXBio to raise $175M in of­fer­ing; Bio­Elec­tron clos­es $40M to prep late-stage mi­to­chon­dr­i­al drug

→ Just a cou­ple days af­ter an­nounc­ing some mixed pipeline up­dates that yo-yoed the stock, gene ther­a­py com­pa­ny Re­genXBio $RGNX is trot­ting out news of a stock of­fer­ing to­tal­ing $175 mil­lion. The pa­per­work was ac­tu­al­ly filed on the same day as their pipeline up­dates, which could have con­tributed to in­vestors’ mood­i­ness ear­li­er this week. The Rockville, MD-based com­pa­ny plans to sell 2.7 mil­lion shares of its com­mon stock at $65 per share. That’s about fair, as the com­pa­ny’s stock price is hov­er­ing around that mark Fri­day morn­ing. Pro­ceeds, in part, are go­ing to­wards the com­pa­ny’s pipeline of in­ves­ti­ga­tion­al ther­a­pies, in­clud­ing RGX-314, RGX-501, RGX-111, and RGX-121, ac­cord­ing to the com­pa­ny’s SEC state­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER